Silence Therapeutics plc (SLN) Revenue History
Annual and quarterly revenue from 2014 to 2025
Compound Annual Growth Rate (CAGR)
Loading revenue history...
SLN Revenue Growth
Revenue Breakdown (FY 2025)
SLN's revenue distribution by segment and geography for fiscal year 2025
By Product/Segment
By Geography
SLN Revenue Analysis (2014–2025)
As of May 8, 2026, Silence Therapeutics plc (SLN) generated trailing twelve-month (TTM) revenue of $559,000, reflecting significant decline in growth of -99.9% year-over-year. The most recent quarter (Q4 2025) recorded $34,000 in revenue, down 78.6% sequentially.
Looking at the longer-term picture, SLN's 5-year compound annual growth rate (CAGR) stands at -36.7%, indicating revenue contraction over this period. The company achieved its highest annual revenue of $43.3 million in 2024.
Revenue diversification analysis shows SLN's business is primarily driven by Research Collaboration Income (100%). With over half of revenue concentrated in Research Collaboration Income, the company maintains significant focus in this area while developing other growth vectors.
When compared to Healthcare sector peers including ALNY (+82.6% YoY), ARWR (+14.1% YoY), and SRPT (-2.2% YoY), SLN has underperformed the peer group in terms of revenue growth. Compare SLN vs ALNY →
SLN Revenue vs Peers
Revenue metrics vs comparable public companies
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| SLNCurrent | $559,000 | -99.9% | -36.7% | -16056.0% | |
 ALNY | $3.7B | +82.6% | +49.8% | 13.5% | |
 ARWR | $829M | +14.1% | +56.6% | 11.9% | |
 SRPT | $2.2B | -2.2% | +32.4% | -29.9% | |
 NTLA | $68M | +16.9% | +3.1% | -651.7% | |
 IONS | $944M | +47.5% | +5.3% | -40.5% |
SLN Historical Revenue Data (2014–2025)
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $559K | -98.7% | $344K | 61.5% | $-89,753,000 | -16056.0% |
| 2024 | $43.3M | +70.5% | $31.4M | 72.7% | $-63,319,000 | -146.4% |
| 2023 | $25.4M | +17.2% | $15.1M | 59.3% | $-49,604,000 | -195.5% |
| 2022 | $21.7M | +74.4% | $8.2M | 37.8% | $-61,040,000 | -281.9% |
| 2021 | $12.4M | +126.6% | $5.0M | 39.9% | $-45,814,000 | -369.0% |
| 2020 | $5.5M | +2145.5% | $1.7M | 31.3% | $-35,847,000 | -654.3% |
| 2019 | $244K | - | $244K | 100.0% | $-22,734,000 | -9317.2% |
| 2018 | $0 | -100.0% | $-9,743,000 | - | $-20,571,000 | - |
| 2017 | $16K | -97.9% | $-7,927,000 | -49543.8% | $-14,391,000 | -89943.8% |
| 2016 | $770K | - | $-7,941,000 | -1031.3% | $-11,906,000 | -1546.2% |
See SLN's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs SLN Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare SLN vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonSLN — Frequently Asked Questions
Quick answers to the most common questions about buying SLN stock.
Is SLN's revenue growth accelerating or slowing?
SLN revenue declined -99.9% year-over-year, contrasting with the 5-year CAGR of -36.7%. TTM revenue fell to $559000.00. This reverses the prior growth trend.
What is SLN's long-term revenue growth rate?
Silence Therapeutics plc's 5-year revenue CAGR of -36.7% reflects the variable expansion pattern. Current YoY growth of -99.9% is below this long-term average.
How is SLN's revenue distributed by segment?
SLN reports revenue by product line and geographic region. Annual and quarterly breakdowns from 2014-2025 are available for download. Segment mix reveals concentration and diversification trends.